Glenmark Pharmaceuticals, a leading research-based global pharmaceutical company, is planning to strengthen its position in US, the world's largest drug market, by launching more generic copies. The company is currently in the process of filing a large number of ANDAs (Abbreviated New Drug Applications) with the US Food and Drug Administration (FDA). The company’s US formulations business, with sales of $335 million in FY14, contributes 34% to its consolidated revenues.
Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company and ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues as per SCRIP 100 Rankings. Glenmark has several molecules in various stages of clinical development and primarily focused in the areas of Inflammation, Pain and Oncology. The company has significant presence in branded formulations across emerging economies including India.
